Country: Canada
Language: English
Source: Health Canada
INFLIXIMAB
CELLTRION HEALTHCARE CO LTD
L04AB02
INFLIXIMAB
120MG
SOLUTION
INFLIXIMAB 120MG
SUBCUTANEOUS
15G/50G
Prescription
DISEASE-MODIFYING ANTIRHEUMATIC AGENTS
Active ingredient group (AIG) number: 0144162002; AHFS:
APPROVED
2021-01-28
_REMSIMA_ _TM_ _ SC Product Monograph _ _Page 1 of 81 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR REMSIMA TM SC (infliximab injection) Solution for Subcutaneous Injection, 120 mg / ml PROFESSED STANDARD Biological Response Modifier Manufactured by: Celltrion Healthcare Co., Ltd. 19, Academy-ro 51 beon-gil, Yeonsu-gu, Incheon Republic of Korea 22014 Imported and distributed by: Celltrion Healthcare Canada Limited 121 King Street W., Suite #1010 Toronto, Ontario M5H 3T9 Date of Initial Approval: Jan 28, 2021 Date of Revision: Feb 15, 2024 Submission Control No: 272981 _Remsima SC_ _® _ _Product Monograph _ _Page 2 of 81 _ RECENT MAJOR LABEL CHANGES 1 INDICATIONS [02/2024] 4 DOSAGE AND ADMINITRATION, 4.2 Recommended Dose and Dosage Adjustment, 4.4 Administration [02/2024] 7 WARNINGS AND PRECAUTIONS [02/2024] 8 ADVERSE REACTIONS, 8.2 Clinical Trial Adverse Reactions, 8.3 Less Common Clinical Trial Adverse Drug Reactions, 8.5 Post-Market Adverse Reactions [02/2024] 10 CLINICAL PHARMACOLOGY, 10.3 Pharmacokinetics [02/2024] 14 CLINICAL TRIALS, 14.1 Clinical Trials by Indication, 14.4 Immunogenicity, [02/2024] TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .................................................................. 4 1 INDICATIONS ................................................................................................................... 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ......................................................... 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.1 Dosing Considerations ......................... Read the complete document